As most Gulf markets rally on the back of positive corporate earnings, despite the pressure from fluctuating oil prices, investors are increasingly eyeing opportunities in the Middle East's dynamic economic landscape. With solid fundamentals in non-oil sectors and enhanced market access for foreign investors, identifying stocks with strong growth potential could be key to capitalizing on these favorable conditions.

Top 10 Undiscovered Gems With Strong Fundamentals In The Middle East

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Nofoth Food Products	NA	21.36%	25.28%	★★★★★★
Sure Global Tech	NA	10.11%	15.42%	★★★★★★
Analyst I.M.S. Investment Management Services	NA	31.20%	44.24%	★★★★★★
Saudi Azm for Communication and Information Technology	NA	17.87%	23.67%	★★★★★★
Terminal X Online	12.94%	13.43%	44.27%	★★★★★★
MOBI Industry	13.81%	5.68%	19.85%	★★★★★★
Najran Cement	14.49%	-4.20%	-30.16%	★★★★★★
Bilici Yatirim Sanayi ve Ticaret	0.02%	17.80%	17.99%	★★★★★☆
Etihad GO Telecom	NA	38.31%	54.97%	★★★★☆☆
Birikim Varlik Yonetim Anonim Sirketi	59.38%	42.42%	36.01%	★★★★☆☆

Here we highlight a subset of our preferred stocks from the screener.

Emirates Insurance Company P.J.S.C (ADX:EIC)

Simply Wall St Value Rating: ★★★★★★

Overview: Emirates Insurance Company P.J.S.C. operates in the general insurance and reinsurance sectors across the United Arab Emirates, the United States, and Europe with a market capitalization of AED1.04 billion.

Operations: Emirates Insurance derives its revenue primarily from underwriting, contributing AED2.41 billion, and investments, adding AED86.04 million.

Emirates Insurance, a noteworthy player in the Middle East's insurance sector, showcases robust financial health with high-quality earnings and no debt over the past five years. The company reported a 14.8% earnings growth last year, though it trailed behind the industry average of 36.6%. Its price-to-earnings ratio stands at an attractive 7.5x against the AE market's 12.2x, indicating potential value for investors. Recent results highlight net income of AED 39 million for Q3 and AED 108 million for nine months ending September 2025, with basic EPS rising from AED 0.19 to AED 0.26 year-over-year in Q3.

Al Hassan Ghazi Ibrahim Shaker (SASE:1214)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Al Hassan Ghazi Ibrahim Shaker Company, with a market cap of SAR1.39 billion, operates in Saudi Arabia through its trading, wholesale, and maintenance services for spare parts, electronic equipment, household equipment, and air-conditioners.

Operations: Shaker Company generates revenue primarily from its Heating, Ventilation and Air-Conditioning Solutions (HVAC) segment, contributing SAR1.03 billion, and the Home Appliances segment, contributing SAR375.24 million. The company's net profit margin reflects its financial efficiency in managing costs relative to its revenue streams.

Shaker stands out in the Middle East as a promising player with its earnings growing 13.7% in the past year, surpassing industry growth of 7.1%. The company's debt to equity ratio improved from 60.5% to 50% over five years, though its net debt to equity remains high at 43.2%. With a price-to-earnings ratio of 17.4x, Shaker is considered good value compared to the Saudi Arabian market average of 17.6x. Despite shareholder dilution last year, Shaker's earnings quality and forecasted annual growth rate of 19.27% suggest potential for future expansion within the trade distributors sector.

BrainsWay (TASE:BWAY)

Simply Wall St Value Rating: ★★★★★★

Overview: BrainsWay Ltd. is a company that develops and sells noninvasive neurostimulation treatments for mental health disorders across the United States, East Asia, and internationally, with a market cap of ₪1.41 billion.

Operations: BrainsWay generates revenue primarily from the development and commercialization of its Deep TMS System, amounting to $49.09 million.

BrainsWay, a nimble player in the medical equipment sector, has been making waves with its innovative Deep Transcranial Magnetic Stimulation (Deep TMS) technology. The company recently secured FDA approval for its ProlivTMRx system, marking a significant milestone as it becomes the first at-home neuromodulation treatment for major depressive disorder. Financially, BrainsWay reported earnings growth of 316% over the past year and is trading at 68% below estimated fair value. With no debt on its books and high-quality earnings, this company seems well-positioned to capitalize on expanding regulatory recognition and market demand for advanced mental health solutions.

Where To Now?

• Discover the full array of 194 Middle Eastern Undiscovered Gems With Strong Fundamentals right here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.